References
- Jordan TJ, Lewit EM, Reichman LB. Isoniazid preventive therapy for tuberculosis: decision analysis considering ethnicity and gender. Am Rev Respir Dis 1991; 144(6): 1357–60
- Robson SC, Pillans P, Willcox PA. Treatment of tuberculosis in patients with preexisting liver disease or following hepatotoxic drug reactions. S Aft Med J 1993; 83(6): 432–4
- Gent WL, Seifert HI, Parkin DP, et al. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. Eur J Clin Pharmacol 1992; 43(2): 131–6
- Weber WW, Hein DW, Litwin A, et al. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer. Fed Proc 1983; 42(14): 3086–97
- Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129(1): 58–61
- Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990; 150(12): 2517–22
- Saltpeter SR. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med 1993; 159(5): 560–4
- Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest 1992 May; 101(5): 1298–301
- Mitchell I, Wendon J, Fitt S, et al. Antituberculous therapy and acute liver failure. Lancet 1995; 345(8949): 555–6
- Mergelsberg M, Weber M, Musch E. Change in liver size caused by antitubercular combination therapy. Pneumologie 1990; 44(6): 806–14
- Pilheu JA, De Salvo MC, Koch O. Liver alterations in antituberculosis regimens containing pyrazinamide. Chest 1981; 80(6): 720–2
- Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67(2): 99–108
- Singh J, Arora A, Garg PK, et al. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71(836): 359–62
- Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21(4): 929–32
- Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99(2): 465–71
- Cross FS, Long MW, Banner AS, et al. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a US Public Health Service cooperative therapy trial. Am Rev Respir Dis 1991; 143: 1350–2
- Kumar A, Misra PK, Mehotra R, et al. Hepatotoxicity of rifampin and isoniazid: is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143(6): 1350–2
- Wu JC, Lee SD, Yeh PF, et al. Isoniazidrifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98(2): 502–4
- Krishnaswamy K, Prasad CE, Murthy KJ. Hepatic dysfunction in undernourished patients receiving isoniazid and rifampicin. Tropical & Geographical Med 1991; 43(1–2): 156–60
- Joint Tuberculosis Committee. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990; 45(5): 403–8
- Tuberculosis Committee, Canadian Thoracic Society. Essentials of tuberculosis control for the practising physician. Can Med Assoc J 1994; 150(10): 1561–71
- Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149(5): 1359–74